年龄对非精子瘤丸癌患者死亡率的递增剂量-反应效应
Reha-Baris Incesu1, Mattia Luca Piccinelli2, Simone Morra3
1Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Urologic oncology
|February 7, 2026
概括
40岁及以上非精子瘤丸癌患者的年龄增加与癌症特异性死亡率的剂量反应影响有关. 年龄较大的年龄组在所有阶段都显示出明显更高的死亡风险.
科学领域:
- 在瘤学瘤学.
- 癌症流行病学 癌症流行病学
背景情况:
- 高龄 (≥40岁) 是一个已知的高丸癌特异性死亡率 (CSM) 的风险因素.
- 在老年非血瘤患者的小组中,年龄对剂量反应的增量影响的存在仍然不清楚.
研究的目的:
- 调查40岁及以上的当代非精髓瘤丸癌患者中年龄增加和CSM之间剂量反应关系的假设.
- 分析不同阶段非精子瘤的与年龄相关的死亡风险.
主要方法:
- 从2004年至2018年使用了监测,流行病学和最终结果 (SEER) 数据库.
- 采用卡普兰-梅尔图和多变量考克斯回归模型来评估年龄对CSM的影响.
- 基于癌症阶段 (I,II,III) 进行了分层分析.
主要成果:
- 这项研究包括13,679名非血瘤患者,19%的患者年龄≥40岁.
- 与40岁以下的患者相比,随着年龄的增加 (40-44,45-52,≥53) 显示出剂量-反应相关性与更高的CSM (HR分别为1.4,1.9,3.6).
- 年龄≥53岁在所有阶段显著预测更高的CSM (I阶段HR 4.7,II阶段HR 9.9,III阶段HR 3.0).
结论:
- 在40岁以上的非血瘤患者中,发现了增加年龄对CSM的明确剂量反应效应.
- 这种与年龄相关的死亡风险在整体和特定阶段的分析中都很明显,强调年龄较大是关键的预后因素.
相关概念视频
01:15Drug Dosing: Geriatric Patients
278
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
01:21Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
01:03Dose-Response Relationship: Overview
5.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.2K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
240
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
240
01:22Dose-Response Relationship: Potency and Efficacy
6.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.6K
01:25Dose-Response Relationship: Selectivity and Specificity
9.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.8K